Startups
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
In January, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.
PRESS RELEASES